Herein, we overviewed the role of GIP and GLP-1 in the pathophysiology of type 2 diabetes and systematically reviewed the efficacy and safety of injectable incretin-based therapy added to basal insulin in light of the results of the SURPASS-5 trial
BBR demonstrates robust anti-obesity effects in both preclinical and clinical settings [4, 47, 175, 222, 223]
For substantiation of any statements of fact from the peer-reviewed medical literature, please see the associated videos below
Potential Therapeutic Indications for Systemic Delivery: Immune Modulation: Stabilizing and supporting balanced immune responses Metabolic Enhancement: Assisting in energy balance and lean mass preservation
AbbVies Humira patent portfolio, which the Institute for Clinical and Economic Review (ICER) and researchers at the University of Illinois documented as comprising over 160 patents, is the most cited example of this strategy executed at scale
Para obtener ms informacin, pngase en contacto: Correo electrnico:[email protected] WhatsApp: +86 18992720900
